A Silybin-Phospholipid Complex Prevents Mitochondrial Dysfunction in a Rodent Model of Nonalcoholic Steatohepatitis

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2010-03-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1124/jpet.109.161612PMID 20008062
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Silymarin: A Review of its Clinical Properties in the Management of Hepatic Disorders

  2012cited by this paper
• Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells.

  2009cited by this paper
• Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice.

  2009cited by this paper
• Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia–reperfusion injury

  2008cited by this paper
• Mitochondrial involvement in non-alcoholic steatohepatitis.

  2008cited by this paper
• Alterations of hepatic ATP homeostasis and respiratory chain during development of non‐alcoholic steatohepatitis in a rodent model

  2008cited by this paper
• Polyunsaturated fat in the methionine-choline-deficient diet influences hepatic inflammation but not hepatocellular injury 1 s⃞ Published, JLR Papers in Press, May 27, 2007.

  2007cited by this paper
• Bioenergetics in aging: mitochondrial proton leak in aging rat liver, kidney and heart

  2007influential reference
• Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin.

  2007cited by this paper
• The Effect of a Silybin-Vitamin E-Phospholipid Complex on Nonalcoholic Fatty Liver Disease: A Pilot Study

  2007cited by this paper
• A lipidomic analysis of nonalcoholic fatty liver disease

  2007cited by this paper
• Non-alcoholic steatohepatitis: from cell biology to clinical practice.

  2006cited by this paper
• Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it.

  2006cited by this paper
• Hypothyroidism down-regulates mitochondrial citrate carrier activity and expression in rat liver.

  2006cited by this paper
• Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-Vitamin E complex in rats.

  2005cited by this paper
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005cited by this paper
• The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance.

  2004cited by this paper
• 4-Hydroxynonenal is Markedly Higher in Patients on a Standard Long-term Home Parenteral Nutrition

  2004cited by this paper
• Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress

  2004cited by this paper
• The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease.

  2004cited by this paper
• Silibinin protects mice from T cell-dependent liver injury.

  2003cited by this paper
• Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis

  2003cited by this paper
• Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis.

  2003cited by this paper
• Proton conductance and fatty acyl composition of liver mitochondria correlates with body mass in birds.

  2003cited by this paper
• Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects.

  2003cited by this paper
• Intrinsic and extrinsic uncoupling of oxidative phosphorylation.

  2003cited by this paper
• A convenient one-step extraction of cellular ATP using boiling water for the luciferin-luciferase assay of ATP.

  2002cited by this paper
• In vivo and in organello assessment of OXPHOS activities.

  2002cited by this paper
• Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.

  2001cited by this paper
• Etiopathogenesis of Nonalcoholic Steatohepatitis

  2001cited by this paper
• Dietary choline restriction causes complex I dysfunction and increased H(2)O(2) generation in liver mitochondria.

  2000cited by this paper
• 4‐Hydroxynonenal in the Pathomechanisms of Oxidative Stress

  2000cited by this paper
• Mitochondrial abnormalities in non-alcoholic steatohepatitis.

  1999cited by this paper
• Mitochondrial Oxygen Radical Generation and Leak: Sites of Production in States 4 and 3, Organ Specificity, and Relation to Aging and Longevity

  1999cited by this paper
• Steatohepatitis: a tale of two "hits"?

  1998cited by this paper
• REVIEW: Nonalcoholic steatohepatitis

  1997cited by this paper
• Allometry of mitochondrial proton leak: influence of membrane surface area and fatty acid composition.

  1996cited by this paper
• Guide for the Care and Use of Laboratory Animals

  1996cited by this paper
• Cytoplasmic cellular structures control permeability of outer mitochondrial membrane for ADP and oxidative phosphorylation in rat liver cells.

  1995cited by this paper
• Institute of Laboratory Animal Resources.

  1995cited by this paper
• Comparative pharmacokinetics of silipide and silymarin in rats

  1993cited by this paper
• Body mass dependence of H+ leak in mitochondria and its relevance to metabolic rate

  1993cited by this paper
• A rat fatty liver transplant model.

  1993cited by this paper
• Change in cholesterol levels and in lipid fatty acid composition in safflower oil fed lambs.

  1992cited by this paper
• Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by the silybin-phospholipid complex IdB 1016.

  1992cited by this paper
• Silymarin protects against paracetamol‐induced lipid peroxidation and liver damage

  1992cited by this paper
• Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes.

  1991cited by this paper
• Uncouplers of oxidative phosphorylation.

  1990cited by this paper
• Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver.

  1989cited by this paper
• A comparison of mitochondrial respiration and membrane lipid composition in the rat and marmoset following dietary lipid supplementation.

  1984cited by this paper
• Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.

  1980cited by this paper
• Uncouplers of oxidative phosphorylation.

  1980cited by this paper
• [58] Uncouplers of oxidative phosphorylation

  1979cited by this paper
• The thyroid hormones: a thesis concerning their action.

  1978cited by this paper

• Herbal remedies for hepatic diseases: A review of medicinal herbs in the treatment of liver disorders

  2026cites this paper
• Therapeutic Potential of Quercetin, Silibinin, and Crocetin in a High-Fat Diet-Induced Mouse Model of MASLD: The Role of CD36 and PLIN3

  2025cites this paper
• Silybin attenuates avermectin-induced oxidative damage in carp respiration by modulating the cGAS-STING pathway and endoplasmic reticulum stress

  2024cites this paper
• Silybin: A Review of Its Targeted and Novel Agents for Treating Liver Diseases Based on Pathogenesis

  2024cites this paper
• Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches

  2024cites this paper
• Novel Strategies Enhancing Bioavailability and Therapeutical Potential of Silibinin for Treatment of Liver Disorders

  2024cites this paper
• Natural compounds proposed for the management of non-alcoholic fatty liver disease

  2024cites this paper
• Beneficial effects of silibinin on serum lipids, bile acids, and gut microbiota in methionine-choline-deficient diet-induced mice

  2023cites this paper
• Ameliorative effects of silybin against avermectin-triggered carp spleen mitochondrial dysfunction and apoptosis through inhibition of PERK-ATF4-CHOP signaling pathway

  2023cites this paper
• Natural Products for the Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Review

  2023cites this paper
• Berberine-silybin salt achieves improved anti-nonalcoholic fatty liver disease effect through regulating lipid metabolism.

  2023cites this paper
• Dietary Supplementation of Silybum marianum Seeds Improved Growth Performance and Upregulated Associated Gene Expression of Muscovy Ducklings (Cairina moschata)

  2022cites this paper
• The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products

  2022cites this paper
• Solvent Free Twin Screw Processed Silybin Nanophytophospholipid: In Silico, In Vitro and In Vivo Insights

  2022cites this paper
• Combined hepatoprotective pharmacotherapy for liver disease

  2022cites this paper
• Hepatoprotective effect of silymarin on fructose induced nonalcoholic fatty liver disease in male albino wistar rats

  2021cites this paper
• Mitochondrial Targeting Therapeutics: Promising Role of Natural Products in Non-alcoholic Fatty Liver Disease

  2021cites this paper
• Effects of anticancer drugs on the cardiac mitochondrial toxicity and their underlying mechanisms for novel cardiac protective strategies.

  2021cites this paper
• The role of biofactors in the prevention and treatment of age‐related diseases

  2021cites this paper
• Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.

  2021cites this paper
• Chapter 11: Silymarin

  2020cites this paper
• Cerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease

  2019cites this paper
• Superior silybin bioavailability of silybin–phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy volunteers*

  2019cites this paper
• Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway

  2019cites this paper
• Herbal drug discovery for the treatment of nonalcoholic fatty liver disease

  2019cites this paper
• Role of silibinin in the management of diabetes mellitus and its complications

  2018cites this paper
• Silymarin prevents acetaminophen-induced hepatotoxicity in mice

  2018cites this paper
• New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis

  2018cites this paper
• Antidotal Assessment of Hydroethanol Root Extract of Curcuma longa L. (Turmeric) against Chemically-induced Hepatic Neoplasm in Wistar Rats

  2018cites this paper
• The potential of flavonoids in the treatment of non-alcoholic fatty liver disease

  2017cites this paper
• Protective Effects and Mechanism of Meretrix meretrix Oligopeptides against Nonalcoholic Fatty Liver Disease

  2017cites this paper
• Silibinin Restores NAD+ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver

  2017cites this paper
• Silymarin protects against renal injury through normalization of lipid metabolism and mitochondrial biogenesis in high fat‐fed mice

  2017cites this paper
• Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review.

  2016cites this paper
• Effects of Mediterranean diet supplemented with silybin–vitamin E–phospholipid complex in overweight patients with non-alcoholic fatty liver disease

  2015cites this paper
• Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives

  2015cites this paper
• Title Current Status of Herbal Medicines in Chronic Liver Disease Therapy : The Biological Effects , Molecular Targets and Future Prospects

  2015cites this paper
• Current Status of Herbal Medicines in Chronic Liver Disease Therapy: The Biological Effects, Molecular Targets and Future Prospects

  2015cites this paper
• Recent advances in the nanotechnology-based drug delivery of Silybin.

  2014cites this paper
• Silymarin ameliorates fructose induced insulin resistance syndrome by reducing de novo hepatic lipogenesis in the rat.

  2014cites this paper
• Experimental models of non-alcoholic fatty liver disease in rats.

  2014cites this paper
• Polyphenols and Flavonoids in Controlling Non-Alcoholic Steatohepatitis

  2014cites this paper
• Reactive Oxygen Species (ROS) and Liver Disease Therapy

  2014cites this paper
• Acetaminophen‐induced liver injury in obesity and nonalcoholic fatty liver disease

  2014cites this paper
• Herbal Medicines for the Treatment of Nonalcoholic Steatohepatitis: Current Scenario and Future Prospects

  2014cites this paper
• Silybin exerts antioxidant effects and induces mitochondrial biogenesis in liver of rat with secondary biliary cirrhosis.

  2014cites this paper
• A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes.

  2013cites this paper
• Milk thistle and its derivative compounds: a review of opportunities for treatment of liver disease.

  2013cites this paper
• Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies

  2013cites this paper
• Down-regulation of LPCAT expression increases platelet-activating factor level in cirrhotic rat liver: potential antiinflammatory effect of silybin.

  2013cites this paper
• Role of microRNAs in the immune system, inflammation and cancer.

  2013cites this paper
• Milk thistle to treat non-alcoholic fatty liver disease: dream or reality?

  2013cites this paper
• A new approach to facilitate diagnosis of nonalcoholic fatty liver disease through a galactose single point method in rats with fatty liver.

  2013cites this paper
• Free radical biology for medicine: learning from nonalcoholic fatty liver disease.

  2013cites this paper
• Oxysterols and redox signaling in the pathogenesis of non-alcoholic fatty liver disease

  2013cites this paper
• Silymarin in the prevention and treatment of liver diseases and primary liver cancer.

  2012cites this paper
• Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis.

  2012cites this paper
• Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis.

  2012cites this paper
• Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial.

  2012cites this paper
• Contemporary overview on clinical trials and future prospects of hepato-protective herbal medicines.

  2012cites this paper
• Intrauterine Growth Retardation Increases the Susceptibility of Pigs to High-Fat Diet-Induced Mitochondrial Dysfunction in Skeletal Muscle

  2012cites this paper
• Adenosine A(2a) receptor stimulation prevents hepatocyte lipotoxicity and non-alcoholic steatohepatitis (NASH) in rats.

  2012cites this paper
• Mitochondrial dysfunction in nonalcoholic steatohepatitis

  2011cites this paper
• Silybin and the liver: from basic research to clinical practice.

  2011cites this paper
• Full-spectrum antioxidant therapy featuring astaxanthin coupled with lipoprivic strategies and salsalate for management of non-alcoholic fatty liver disease.

  2011cites this paper
• Milk thistle for treatment of nonalcoholic fatty liver disease

  2011cites this paper
• Targeting mitochondria: a new promising approach for the treatment of liver diseases.

  2010cites this paper